Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies.

ABSTRACT:

Introduction

Mesothelin (MSLN) is overexpressed in a wide variety of cancers with few therapeutic options and has recently emerged as an attractive target for cancer therapy, with a large number of approaches currently under preclinical and clinical investigation. In this respect, developing mesothelin specific tracers as molecular companion tools for predicting patient eligibility, monitoring then response to mesothelin-targeting therapies, and tracking the evolution of the disease or for real-time visualisation of tumours during surgery is of growing importance.

Methods

We generated by phage display a nanobody (Nb S1) and used enzymatic approaches were used to site-directed conjugate Nb S1 with either ATTO 647N fluorochrome or NODAGA chelator for fluorescence and positron

SUBMITTER: Benloucif A 

PROVIDER: S-EPMC10303918 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature